Grace Therapeutics, INC 8-K filings
NASDAQ
8-K: Acasti Pharma's Phase 3 Trial Reaches 50% Enrollment Milestone, NDA Submission Expected in 2025
Acasti Pharma announced that its pivotal Phase 3 STRIVE-ON safety trial for GTX-104 has exceeded the 50% enrollment milestone, with completion of patient enrollment anticipated in late 2024 to early 2025.
NASDAQ
Acasti Pharma announced its fiscal year 2024 financial results and provided a business update, highlighting the progress of its GTX-104 clinical trial and a projected cash runway into the second quarter of 2026.
NASDAQ
Acasti Pharma is developing GTX-104, an intravenous nimodipine formulation, to address the limitations of oral nimodipine in treating aneurysmal subarachnoid hemorrhage (aSAH), with a Phase 3 trial underway and a potential NDA submission in 2025.
NASDAQ
Acasti Pharma announced its third fiscal quarter 2024 results, highlighting progress with its GTX-104 clinical trial and an extended cash runway into the second quarter of 2026.